Tuesday, December 06, 2011

Clinical Trials: EVP-6124 Phase 2b Clinical Trial in Schizophrenia

From Drug Discovery & Development:

Positive Study Results for Schizophrenia Drug
Drug Discovery & Development
December 05, 2011

"EnVivo Pharmaceuticals announced the analysis of a completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia."

Read the full report

No comments: